SOLIDARITY trials

The drug candidates for repurposing are imatinib, a cancer drug; infliximab, an antibody; and artesunate, an anti-malarial drug. The tests seek to explore possible drugs that can be repurposed to treat severely affected COVID-19 patients

None of the four drug/drug combinations that were deployed in the WHO’s SOLIDARITY trial were found to be effective in reducing mortality, not even the much-hyped anti-viral drug Remdesivir